How precision and personalized medicine private equity performed in the pharmaceutical industry in Q2 2023
In value terms, precision and personalized medicine-related deal activity decreased by % in Q2 2023 compared with the previous quarter’s total of and fell by 83% as compared to Q2 2022. Related deal volume remained flat in Q2 2023 versus the previous quarter.
For further understanding of GlobalData’s Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.
Source link
#precision #personalized #medicine #private #equity #performed #pharmaceutical #industry
